Clinical trial
Immunopharmacological Effects of Rituximab in Atopic Dermatitis
NCT00267826 · University of Bern, Other · Completed
Key facts
| NCT number | NCT00267826 |
|---|---|
| Title | Immunopharmacological Effects of Rituximab in Atopic Dermatitis |
| Official title | Open-Label, Single Center Study to Evaluate the Immunopharmacological Effects of Rituximab in Patients With Atopic Dermatitis |
| Lead sponsor | University of Bern, Other |
| Collaborators | Hoffmann-La Roche Industry Swiss National Science Foundation |
| Status | Completed |
| Study type | Interventional |
| Conditions | Dermatitis, Atopic |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 6 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Dec 21, 2005 |
| Last update posted | Jun 17, 2008 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: